Andarix Pharmaceuticals Pancreatic Cancer Therapy Selected for Abstract Publication at the 2014 ASCO Meeting
Tozaride Targeted Therapy Shows Tumor Reduction in Animal Model
Somerville, Massachusetts (PRWEB) May 28, 2014
Andarix Pharmaceuticals, a clinical stage company, announces that its Tozaride targeted pancreatic cancer therapy has been selected for abstract publication at the 2014 ASCO meeting in Chicago, IL, May 30-June 4.
The abstract – e15224: Effect of rhenium Re188-P2045 (Tozaride) on tumor growth in the AR42J rat pancreatic tumor xenograft nude mouse model – is available online at ASCO.com. Tozaride showed a significant reduction in pancreatic tumor size in the animal model. “We are pleased to have been selected by ASCO to publish our preclinical study of targeted therapy in pancreatic cancer as part of the annual meeting. This new study is another demonstration of the broad application of our targeted technology for cancer therapy,” says Chris Adams, Chief Executive Officer.
Tozaride is a novel, best-in-class therapy for lung, pancreatic and other cancers based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Pancreatic cancer is responsible for significant cancer mortality in the United States, with over 50,000 new diagnoses of pancreatic cancer and over 50,000 deaths attributable to this disease annually. To learn more about Andarix, please visit http://www.andarix.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/05/prweb11885142.htm